FROM AUTOIMMUNITY TO INNOVATION: A NARRATIVE REVIEW OF VITILIGO AND ITS MANAGEMENT
Abstract
Background: Vitiligo is a chronic skin disorder characterized by the development of hypopigmented or depigmented macules and patches, resulting from the loss of functional melanocytes in the affected areas. It is estimated to affect approximately 0.5% to 4% of the global population. Although the exact etiology remains unclear, vitiligo is considered an acquired, multifactorial condition involving complex interactions.
Aim: To summarize current knowledge on vitiligo, focusing on its pathogenesis, clinical presentation, diagnostic principles, and therapeutic strategies.
Methodology: Literature review was conducted using PubMed, the Cochrane Library, and Google Scholar databases.
Results: Vitiligo is now widely regarded as an autoimmune disorder. Current management centers on immune modulation through topical and systemic agents, phototherapy, and, in selected cases, surgical intervention. Adjunctive measures including camouflage techniques, nutritional optimization, and psychological support play an important role in improving quality of life.
Conclusions: Vitiligo results from complex autoimmune and oxidative processes leading to melanocyte destruction. First-line treatment typically includes topical corticosteroids or calcineurin inhibitors, with phototherapy serving as an effective and well-established adjunct. Combination and targeted immunomodulatory therapies, such as JAK inhibitors, represent promising future directions. Despite notable advances, complete and durable repigmentation remains uncommon, highlighting the need for continued research and individualized patient care.
References
Czajkowski, R., Placek, W., Flisiak, I., Krasowska, D., Maj, J., Marchlewicz, M., Reich, A., Wolska, H., & Rudnicka, L. (2019). Vitiligo. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatol Rev / Przegląd Dermatologiczny, 106, 1–15. https://doi.org/10.5114/dr.2019.83440
Krüger, C., Schallreuter K. U. (2015). Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Dermato‑Venereologica, 95(5), 553–558. https://doi.org/10.2340/00015555‑1981
Silverberg, J. I., & Silverberg, N. B. (2014). Quality of life impairment in children and adolescents with vitiligo. Pediatric Dermatology, 31(3), 309–318. https://doi.org/10.1111/pde.12226
P.E. Grimes, Vitiligo: Management and prognosis [online], w: UpToDate, https://www.uptodate.com/contents/vitiligo-management-and-prognosis.
Castanet, J., & Ortonne, J.-P. (1997). Pathophysiology of vitiligo. Clinics in Dermatology, 15(6), 845–851. https://doi.org/10.1016/S0738-081X(97)00125-9
Bergqvist, C., Ezzedine, K. (2020). Vitiligo: A review. Dermatology, 236(6), 571–592. https://doi.org/10.1159/000506103
Matz H., Tur E. Vitiligo. Current Problems in Dermatology, 2007.
Marchioro, H. Z., Silva de Castro, C. C., Fava, V. M., Sakiyama, P. H., Dellatorre, G., & Miot, H. A. (2022). Update on the pathogenesis of vitiligo. Anais Brasileiros de Dermatologia, 97(4), 478‑490. https://doi.org/10.1016/j.abd.2021.09.008
Palermo B., Campanelli R., Garbelli S., Mantovani S., Lantelme E., Brazzelli V., Ardigó M., Borroni G., Martinetti M., Badulli C., et al. Specific Cytotoxic T Lymphocyte Responses against Melan-A/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex/Peptide Tetramers: The Role of Cellular Immunity in the Etiopathogenesis of Vitiligo. J. Investig. Dermatol. 2001;117:326–332. doi: 10.1046/j.1523-1747.2001.01408.x.
van den Boorn J.G., Konijnenberg D., Dellemijn T.A.M., van der Veen J.P.W., Bos J.D., Melief C.J.M., Vyth-Dreese F.A., Luiten R.M. Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. J. Investig. Dermatol. 2009;129:2220–2232. doi: 10.1038/jid.2009.32.
Whitton, M. E., Pinart, M., Batchelor, J., Leonardi‑Bee, J., González, U., Jiyad, Z., Eleftheriadou, V., & Ezzedine, K. (2015, February 24). Interventions for vitiligo. Cochrane Database of Systematic Reviews, (2), CD003263. https://doi.org/10.1002/14651858.CD003263.pub5
Ghafouriani, E., Ghafourian, S., Sadeghifard, N., Mohebp, R., Shokoohinp, Y., Nezamoleslamp, S., & Hamat, R. A.(2014). Vitiligo: Symptoms, pathogenesis and treatment. International Journal of Immunopathology and Pharmacology, 27(4), 485–489.
Dyer, J. M., & Foy, V. M. (2022). Revealing the unseen: A review of Wood’s lamp in dermatology. Journal of Clinical and Aesthetic Dermatology, 15(6), 25–30. PMID: 35783566. PMCID: PMC9239119.
Dahir, A. M., & Thomsen, S. F. (2018, October). Comorbidities in vitiligo: Comprehensive review. International Journal of Dermatology, 57(10), 1157–1164. https://doi.org/10.1111/ijd.14166
Neema, S., & Elston, D. M. (2022, July 20). Vitiligo workup. Medscape. Retrieved from https://www.medscape.com
Ezzedine, K., Lim, H. W., Suzuki, T., Katayama, I., Hamzavi, I., Lan, C. C. E., Goh, B. K., Anbar, T., Silva de Castro, C., Lee, A. Y., Parsad, D., van Geel, N., Le Poole, I. C., Oiso, N., Benzekri, L., Spritz, R., Gauthier, Y., Hann, S. K., Picardo, M., & Taieb, A., on behalf of the Vitiligo Global Issues Consensus Conference panelists. (2012). Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell & Melanoma Research, 25(3), E1–E13. https://doi.org/10.1111/j.1755-148X.2012.00997.x
Gianfaldoni, S., Wollina, U., Tchernev, G., Lotti, J., França, K., & Lotti, T. (2018). Vitiligo in Children: A Review of Conventional Treatments. Open Access Macedonian Journal of Medical Sciences, 6(1), 213–217. https://doi.org/10.3889/oamjms.2018.054
Gianfaldoni, S., Tchernev, G., Wollina, U., Lotti, J., Satolli, F., França, K., Rovesti, M., & Lotti, T. (2018). Vitiligo in Children: A Better Understanding of the Disease. Open Access Macedonian Journal of Medical Sciences, 6(1), 181–184. https://doi.org/10.3889/oamjms.2018.040
Mahmoud, B. H., Hexsel, C. L., & Hamzavi, I. H. (2008). An update on new and emerging options for the treatment of vitiligo. Skin Therapy Letter, 13(2), 1–6. PMID: 18373041
Renert‑Yuval, Y., Ezzedine, K., Grimes, P., Rosmarin, D., Eichenfield, L. F., Castelo‑Soccio, L., Huang, V., Desai, S. R., Walsh, S., Silverberg, J. I., Paller, A. S., Rodrigues, M., Weingarten, M., Narla, S., Gardner, J., Siegel, M., Ibad, S., & Silverberg, N. B. (2024). Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatology, 160(4), 453–461. https://doi.org/10.1001/jamadermatol.2024.0021PMC+3jamanetwork.com+3OUCI+3
Al-Smadi, K., Ali, M., Alavi, S. E., Jin, X., Imran, M., Leite-Silva, V. R., & Mohammed, Y. (2023). Using a topical formulation of vitamin D for the treatment of vitiligo: A systematic review. Cells, 12(19), 2387. https://doi.org/10.3390/cells12192387
Hossani-Madani, A. R., & Halder, R. M. (2010). Topical treatment and combination approaches for vitiligo: New insights, new developments. Giornale Italiano di Dermatologia e Venereologia, 145(1), 57–78.
Das, A., & Panda, S. (2017). Use of topical corticosteroids in dermatology: An evidence-based approach. Indian Journal of Dermatology, 62(3), 237–250. https://doi.org/10.4103/ijd.IJD_169_17
Kubelis‑López, D. E., Zapata‑Salazar, N. A., Said‑Fernández, S. L., Sánchez‑Domínguez, C. N., Salinas‑Santander, M. A., Martínez‑Rodríguez, H. G., Vázquez‑Martínez, O. T., Wollina, U., Lotti, T., & Ocampo‑Candiani, J. (2021). Updates and new medical treatments for vitiligo (Review). Experimental and Therapeutic Medicine, 22, 797. https://doi.org/10.3892/etm.2021.10229 PMC+1
Bleehen, S. S. (1976). The treatment of vitiligo with topical corticosteroids: Light and electron microscopic studies. British Journal of Dermatology, 94(s12), 43–50. https://doi.org/10.1111/j.1365-2133.1976.tb02268.x
Gawkrodger, D. J., Ormerod, A. D., Shaw, L., Mauri-Sole, I., Whitton, M. E., Watts, M. J., Anstey, A. V., Ingham, J., & Young, K. (2008). Guideline for the diagnosis and management of vitiligo. British Journal of Dermatology, 159(5), 1051–1076. https://doi.org/10.1111/j.1365-2133.2008.08881.x
Wong, R., & Lin, A. N. (2013). Efficacy of topical calcineurin inhibitors in vitiligo. International Journal of Dermatology, 52(5), 491–496. https://doi.org/10.1111/j.1365-4632.2012.05697.x
Wong, E., & Kurian, A. (2016). Off‑Label uses of topical calcineurin inhibitors. STL, 21(1)
Huang, F., Hu, D., Fan, H., Hu, B., Liu, Y., Dong, W., Liu, X., Li, Y., Yan, D., Ding, R., Niu, S., Chen, L., Nie, X., & Fang, Y. (2025). Efficacy and safety of Janus kinase inhibitors in patients with vitiligo: A systematic review and meta-analysis. Clinical Pharmacology & Therapeutics, 117(3), 659–669. https://doi.org/10.1002/cpt.3538
Ferreira, C., King, B., & Torres, T. (2025). JAK inhibitors for the treatment of vitiligo: Current evidence and emerging therapeutic potential. Drugs, Advance online publication. https://doi.org/10.1007/s40265-025-02246-1
Barros, N. de M., Sbroglio, L. L., Buffara, M. de O., Baka, J. L. C. e S., Pessoa, A. de S., & Azulay-Abulafia, L. (2021). Phototherapy. Anais Brasileiros de Dermatologia, 96(4), 397–407. https://doi.org/10.1016/j.abd.2021.03.001
Bae, J. M., Jung, H. M., Hong, B. Y., Lee, J. H., Choi, W. J., Lee, J. H., & Kim, G. M. (2017). Phototherapy for vitiligo: A systematic review and meta-analysis. JAMA Dermatology, 153(7), 666–674. https://doi.org/10.1001/jamadermatol.2017.0002
Frączek, A., Kasprowicz-Furmańczyk, M., Placek, W., & Owczarczyk-Saczonek, A. (2022). Surgical treatment of vitiligo. International Journal of Environmental Research and Public Health, 19(8), 4812. https://doi.org/10.3390/ijerph19084812
Ju, H. J., Bae, J. M., Lee, R. W., Kim, S. H., Parsad, D., Pourang, A., Hamzavi, I., Shourick, J., & Ezzedine, K. (2021). Surgical interventions for patients with vitiligo: A systematic review and meta-analysis. JAMA Dermatology, 157(3), 307–316. https://doi.org/10.1001/jamadermatol.2020.5756
Jafarzadeh, A., Pour Mohammad, A., Khosravi, M., Amiri, S., Rasouli, A., Keramati, H., & Goodarzi, A. (2024). A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Research and Technology, 30(3), e13642. https://doi.org/10.1111/srt.13642
Ezzedine, K., Peeva, E., Yamaguchi, Y., Cox, L. A., Banerjee, A., Han, G., Hamzavi, I., Ganesan, A. K., Picardo, M., Thaçi, D., Harris, J. E., Bae, J. M., Tsukamoto, K., Sinclair, R., Pandya, A. G., Sloan, A., Yu, D., Gandhi, K., Vincent, M. S., & King, B. (2023). Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal of the American Academy of Dermatology, 88(2), 395–403. https://doi.org/10.1016/j.jaad.2022.11.005
Dua, I.; Aggarwal, K.; Jain, V.K. Comparative Evaluation of Efficacy and Safety of Calcipotriol versus Tacalcitol Ointment, Both in Combination with NBUVB Phototherapy in the Treatment of Stable Plaque Psoriasis. Photodermatol. Photoimmunol. Photomed. 2017, 33, 275–281, doi:10.1111/phpp.12324.
Abdel-Hamid, S., Ibrahim, H. M., Hameed, A. M., & Hegazy, E. M. (2024). Effectiveness of fractional erbium–YAG laser, microneedling, platelet-rich plasma in localized stable vitiligo patients: Randomized clinical trial. Archives of Dermatological Research, 316(7), 399. https://doi.org/10.1007/s00403-024-03035-8
Gupta, D., Kumari, R., & Thappa, D. M. (2012). Depigmentation therapies in vitiligo. Indian Journal of Dermatology, Venereology and Leprology, 78(1), 49–58. https://doi.org/10.4103/0378-6323.90946
Hamidizadeh, N., Ranjbar, S., Ghanizadeh, A., Parvizi, M. M., Jafari, P., & Handjani, F. (2020). Evaluating prevalence of depression, anxiety and hopelessness in patients with vitiligo on an Iranian population. Health and Quality of Life Outcomes, 18, 20. https://doi.org/10.1186/s12955-020-1278-7
Hedayat, K., Karbakhsh, M., Ghiasi, M., Goodarzi, A., Fakour, Y., Akbari, Z., Ghayoumi, A., & Ghandi, N. (2016). Quality of life in patients with vitiligo: A cross-sectional study based on Vitiligo Quality of Life index (VitiQoL). Health and Quality of Life Outcomes, 14, 86. https://doi.org/10.1186/s12955-016-0504-2
Chang, Y., Zhang, S., Zhang, W., Li, S., & Li, C. (2022). The efficacy and psychoneuroimmunology mechanism of camouflage combined with psychotherapy in vitiligo treatment. Frontiers in Medicine, 9, Article 818543. https://doi.org/10.3389/fmed.2022.818543
Hamada, R., Funasaka, Y., Saeki, H., Serizawa, N., Hagino, T., Yano, Y., Mitsui, H., & Kanda, N. (2024). Dietary habits in adult Japanese patients with vitiligo. Journal of Dermatology, 51(4), 491–508. https://doi.org/10.1111/1346-8138.17163
Ezzedine, K., Tannous, R., Pearson, T. F., & Harris, J. E. (2024). Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. The Journal of Clinical Investigation, 134(9), e175030. https://doi.org/10.1172/JCI175030
Seneschal, J., & Boniface, K. (2023). Vitiligo: Current therapies and future treatments. Dermatology Practical & Conceptual, 13(4 Suppl 2), e2023313S. https://doi.org/10.5826/dpc.1304S2a313S
López-Estebaranz, J. L., García-Zamora, E., & Griffiths-Acha, J. S. (2025). Management of vitiligo: A promising future. Italian Journal of Dermatology and Venereology, 160(3), 248–261. https://doi.org/10.23736/S2784-8671.25.08112-5
Harris, J. E. (2015). Acta Dermato-Venereologica, 95(6), 643–644. https://doi.org/10.2340/00015555-2137
Views:
41
Downloads:
26
Copyright (c) 2025 Katarzyna Malinowska, Elhatra Settaf-Cherif, Joanna Barwacz, Magdalena Adamik, Layla Settaf-Cherif, Marta Czarnowska, Radosław Sciepuro, Mateusz Malinowski, Dagmara Gładysz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
